Shannon Dahl
Fractional Chief Scientific Officer, Chief Business Advisor, Health Care and Bio/Pharma
Advances therapeutics & companies from discovery to the clinic to commercialization. Recognized on 2018 PharmaVOICE 100 list of the most transformational, influential, & inspirational leaders in the global life sciences industry.
>20 Years in Cell & Gene Therapy, Immunology, Biologics, Therapeutics:
• Immunomodulation of T cells, macrophages, cytokines
• Cell therapy, miRNA, mRNA, allogeneic, small molecules, engineered tissues, exosomes (nature's LNP), epigenetic modifications, AAV
• Immune evasion
Therapeutic Areas:
• Autoimmune, immunology, inflammation, ophthalmology, cardiovascular, vascular dysfunction, nephrology, pulmonology, liver, cancer, fibrosis, orthopedics, urology
Translational and Scientific Leadership for Therapeutics:
• Builds strong, differentiated products, platforms & pipelines
• Optimizes fit-for-purpose therapeutics for scientific, clinical & commercial success
• Translates from discovery to Phase 3 trials
• Creates regulatory & payer strategies & datasets
Strategic Business & Operational Leader:
• Establishes a unified scientific, clinical, regulatory & commercial vision
• Maximizes value of technology platforms
• Sets strategy & operationalizes to achieve milestones
• 19 years in board-facing roles
• Serves on strategic & scientific advisory boards
Notable Accomplishments:
• Co-founded Humacyte, a pioneering regenerative medicine therapeutics company (NASDAQ: HUMA). Advanced bioengineered blood vessel platform from discovery to Phase 3 trials, with a path to reimbursement and a path to BLA. Strong pipeline, strategic & commercial partnerships.
• As CSO of Cell Care, and consulting CSO to VC-backed stealth companies: defines scientific vision, leads discovery & translation, builds high-functioning R&D organizations, defines clear strategy to guide priorities, externally communicates scientific value, partner to CEO on corporate strategy & fundraising.
• Co-authored first RMAT designation ever granted by FDA (like Breakthrough), INDs.
• Negotiated value-based reimbursement path with CMS to replace traditional fee-for-service.
• Inventor on 36 issued patents, author of 21 publications, invited speaker at conferences.
• Represented Humacyte in high profile interviews: The Economist, BBC Radio, WebMD, etc.
Views Leadership as a Team Sport:
• Aligns Boards, C-Suite, teams & stakeholders
• Inspires others to achieve shared goals
• Values strengths of colleagues and their leadership to achieve common goals
• Develops others
• Culture-focused